ScaleReady is a Joint Venture formed by Bio-Techne, Fresenius Kabi, and Wilson Wolf. Combining selected offerings from the three partners, the ScaleReady cell therapy manufacturing platform consists of tools and reagents for cell culture, cell activation, gene editing, and cell processing.
Our mission is to enable the field of Cell and Gene Therapy to become established as the most prolific advance in cancer therapy by greatly simplifying the way T cells are manufactured. Our proven platform features G-RexTM, a single-use static bioreactor that dramatically simplifies workflows while consistently delivering higher cell quality and throughput in significantly less space. The ScaleReady platform is flexible, able to generate small and large cell doses, and is easily optimized for centralized or de-centralized manufacturing. Our goal is to make the prospect of T cell therapy practical and viable not just for the hundreds, but for the hundreds of thousands of patients.